Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study

Authors: David Jones, Pol Boudes, Mark G. Swain, Christopher L. Bowlus, Michael Galambos, Bruce R. Bacon, Yvonne Döerffel, Norman Gitlin, Stuart C. Gordon, Joseph A. Odin, David Sheridan, M A Wörns, Virginia Clark, Linsey Corless, Heinz Hartmann, Mark Jonas, Andreas E. Kremer, George Mells, Peter Buggisch, B. Freilich, Cynthia Levy, John M. Vierling, David Bernstein, Marek Hartleb, Ewa Janczewska, Fedja A. Rochling, Hemant Shah, Mitchell L. Shiffman, John H. Smith, Yun‐Jung Choi, Alexandra Steinberg, Mónika Varga, Harinder Chera, Robert L. Martin, Charles A. McWherter, Gideon M. Hirschfield - The Lancet 2017 cited by 186